Recursion Pharmaceuticals

aid: recursion-pharmaceuticals
name: Recursion Pharmaceuticals
description: 'Recursion Pharmaceuticals (NASDAQ: RXRX) is a Salt Lake City-based AI-enabled drug discovery company that operates
  the Recursion Operating System (Recursion OS), a vertically integrated platform combining automated wet-lab cellular phenomics,
  transcriptomics (Trekseq), proteomics, ADME, chemistry, and patient data with machine learning to map biology and design
  drug candidates. The platform runs on BioHive-2, a NVIDIA-built supercomputer ranked among the top global systems and dedicated
  to biopharma workloads, and is fed by 50+ petabytes of proprietary biological and chemical data. In November 2024 Recursion
  completed the acquisition of Exscientia, folding Exscientia''s generative AI chemistry, Centaur Chemist, and clinical pipeline
  into the combined company; Recursion now runs more than 10 clinical and preclinical programs (REC-4881 for FAP, REC-3565
  MALT1 inhibitor, REC-1245 RBM39 for biomarker-enriched solid tumors and lymphomas, REC-617 CDK7 inhibitor, REC-994 for cerebral
  cavernous malformation, REC-2282 for NF2- mutated meningiomas, REC-4209 for IPF, REC-7735 for HSD obesity), 10+ advanced
  discovery programs, and 10+ partnered programs across Roche (Genentech), Bayer, Sanofi, and Merck KGaA (Darmstadt). Recursion
  does not currently expose paid commercial APIs to external developers; assets and data access are delivered through licensing,
  scientific collaborations, and the MapApp web product. Externally, Recursion ships substantial open tooling: the RxRx family
  of open phenomics datasets (RxRx1, RxRx2, RxRx3, RxRx3-core, RxRx19a, RxRx19b) hosted at rxrx.ai and Hugging Face, the OpenPhenom-S/16
  foundation model (released on Hugging Face and Google Cloud''s Model Garden, with Phenom-Beta on NVIDIA BioNeMo), the MolE
  molecular foundation model, the gflownet library for graph and molecular generative modeling, SynFlowNet/synflownet-boltz
  for retrosynthesis-aware molecular design, maes_microscopy (NeurIPS 2023 spotlight masked autoencoders for cell microscopy),
  and rxrx1-utils for the NeurIPS 2019 CellSignal competition. The combination positions Recursion as a Tier-2 AI drug discovery
  provider with no commercial API surface but a meaningful open-source and open-model presence aimed at the computational
  biology research community.'
type: Index
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
position: Provider
access: 3rd-Party
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/recursion-pharmaceuticals.png
tags:
- AI
- Artificial Intelligence
- Drug Discovery
- Biotech
- Pharmaceuticals
- Phenomics
- Cellular Imaging
- Transcriptomics
- Proteomics
- Chemistry
- Machine Learning
- Foundation Models
- Open Datasets
- Open Source Models
- Generative Chemistry
- Oncology
- Rare Disease
- Clinical Trials
- BioHive
- Recursion OS
- MOSAIC
- MapApp
- OpenPhenom
- MolE
- GFlowNet
- RxRx
- Exscientia
url: https://raw.githubusercontent.com/api-evangelist/recursion-pharmaceuticals/refs/heads/main/apis.yml
created: '2026-05-24'
modified: '2026-05-24'
specificationVersion: '0.20'
apis: []
common:
- type: DomainSecurity
  url: security/recursion-pharmaceuticals-domain-security.yml
- type: Website
  url: https://www.recursion.com
- type: Platform
  url: https://www.recursion.com/recursion-os
- type: Pipeline
  url: https://www.recursion.com/pipeline
- type: ClinicalTrials
  url: https://www.recursion.com/clinical-trials
- type: Partnerships
  url: https://www.recursion.com/partners
- type: Publications
  url: https://www.recursion.com/publications
- type: OpenDatasets
  url: https://www.rxrx.ai
- type: MapApp
  url: https://www.rxrx.ai/mapapp
- type: PhenomModel
  url: https://www.rxrx.ai/phenom
- type: HuggingFace
  url: https://huggingface.co/recursionpharma
- type: HuggingFaceModel — OpenPhenom-S/16
  url: https://huggingface.co/recursionpharma/OpenPhenom
- type: HuggingFaceDataset — RxRx3
  url: https://huggingface.co/datasets/recursionpharma/rxrx3
- type: HuggingFaceDataset — RxRx3-core
  url: https://huggingface.co/datasets/recursionpharma/rxrx3-core
- type: GitHubOrganization
  url: https://github.com/recursionpharma
- type: SourceCode — gflownet
  url: https://github.com/recursionpharma/gflownet
- type: SourceCode — MolE (mole_public)
  url: https://github.com/recursionpharma/mole_public
- type: SourceCode — SynFlowNet-Boltz
  url: https://github.com/recursionpharma/synflownet-boltz
- type: SourceCode — MAEs Microscopy
  url: https://github.com/recursionpharma/maes_microscopy
- type: SourceCode — RxRx1 Utils
  url: https://github.com/recursionpharma/rxrx1-utils
- type: SourceCode — RxRx Datasets
  url: https://github.com/recursionpharma/rxrx-datasets
- type: ExternalModel — Phenom-Beta on NVIDIA BioNeMo
  url: https://build.nvidia.com/recursion
- type: InvestorRelations
  url: https://ir.recursion.com
- type: SECFilings
  url: https://ir.recursion.com/financials/sec-filings
- type: Newsroom
  url: https://www.recursion.com/newsroom
- type: Blog
  url: https://www.recursion.com/insights
- type: Careers
  url: https://www.recursion.com/careers
- type: LinkedIn
  url: https://www.linkedin.com/company/recursionpharma
- type: Twitter
  url: https://twitter.com/RecursionPharma
- type: YouTube
  url: https://www.youtube.com/@RecursionPharmaceuticals
- type: StockTicker
  url: https://finance.yahoo.com/quote/RXRX
- type: Acquisition — Exscientia
  url: https://ir.recursion.com/news-releases/news-release-details/recursion-completes-acquisition-exscientia
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com